161Tb is an interesting radionuclide for cancer treatment, showing similar decay characteristics and chemical behavior to clinically-employed 177Lu. The therapeutic effect of 161Tb, however, may be enhanced due to the co-emission of a larger number of conversion and Auger electrons as compared to 177Lu. The aim of this study was to produce 161Tb from enriched 160Gd targets in quantity and quality sufficient for first application in patients. No-carrier-added 161Tb was produced by neutron irradiation of enriched 160Gd targets at nuclear research reactors. The 161Tb purification method was developed with the use of cation exchange (Sykam resin) and extraction chromatography (LN3 resin), respectively. The resultant product (161TbCl3) was characterized and the 161Tb purity compared with commercial 177LuCl3. The purity of the final product (161TbCl3) was analyzed by means of γ-ray spectrometry (radionuclidic purity) and radio TLC (radiochemical purity). The radiolabeling yield of 161Tb-DOTA was assessed over a two-week period post processing in order to observe the quality change of the obtained 161Tb towards future clinical application. To understand how the possible drug products (peptides radiolabeled with 161Tb) vary with time, stability of the clinically-applied somatostatin analogue DOTATOC, radiolabeled with 161Tb, was investigated over a 24-h period. The radiolytic stability experiments were compared to those performed with 177Lu-DOTATOC in order to investigate the possible influence of conversion and Auger electrons of 161Tb on peptide disintegration. Irradiations of enriched 160Gd targets yielded 6–20 GBq 161Tb. The final product was obtained at an activity concentration of 11–21 MBq/μL with ≥99% radionuclidic and radiochemical purity. The DOTA chelator was radiolabeled with 161Tb or 177Lu at the molar activity deemed useful for clinical application, even at the two-week time point after end of chemical separation. DOTATOC, radiolabeled with either 161Tb or 177Lu, was stable over 24 h in the presence of a stabilizer. In this study, it was shown that 161Tb can be produced in high activities using different irradiation facilities. The developed method for 161Tb separation from the target material yielded 161TbCl3 in quality suitable for high-specific radiolabeling, relevant for future clinical application.

Significant amounts of spent uranium dioxide nuclear fuel are accumulating worldwide from decades of commercial nuclear power production. While such spent fuel is intended to be reprocessed or disposed in geologic repositories, out-of-reactor radiation damage from alpha decay can be detrimental to its structural stability. Here we report on an experimental study in which radiation damage in plutonium dioxide, uranium dioxide samples doped with short-lived alpha-emitters and urano-thorianite minerals have been characterized by XRD, transmission electron microscopy, thermal desorption spectrometry and hardness measurements to assess the long-term stability of spent nuclear fuel to substantial alpha-decay doses. Defect accumulation is predicted to result in swelling of the atomic structure and decrease in fracture toughness; whereas, the accumulation of helium will produce bubbles that result in much larger gaseous-induced swelling that substantially increases the stresses in the constrained spent fuel. Based on these results, the radiation-ageing of highly-aged spent nuclear fuel over more than 10000 years is predicted.JRC.E.3-Materials researc

UO ₂ samples doped with 6, 11, 22 mol% lanthanum were examined before and after air oxidation. To verify the formation of uranium–lanthanum‐mixed oxide solid solutions, powder X‐ray diffraction ( XRD ) analyses of the crystalline phases in the materials were carried out. The presence of oxygen vacancies in the La‐doped UO ₂ samples was identified by Raman spectrometry. It was evidenced by changes induced in the Raman spectra by air oxidation. This latter was carried out either by increasing the Raman laser power or by thermally treating the samples at 500 K for 370 h. In addition, oxidation behavior differences of pure and La‐doped UO ₂ samples were reported by comparing XRD and Raman results of the samples before and after air oxidation. It was shown that the concentration of the M ₄ O ₉ (M: U, La) phase increased with increasing content of La, whereas inhibition for the formation of M ₃ O ₈ phase was observed.

The production of novel radionuclides is the first step towards the development of new effective radiopharmaceuticals, and the quality thereof directly affects the preclinical and clinical phases. In this review, novel radiometal production for medical applications is briefly elucidated. The production status of the imaging nuclide ⁴⁴Sc and the therapeutic β^--emitter nuclide ¹⁶¹Tb are compared to their more established counterparts, ⁶⁸Ga and ¹⁷⁷Lu according to their targetry, irradiation process, radiochemistry, and quality control aspects. The detailed discussion of these significant issues will help towards the future introduction of these promising radionuclides into drug manufacture for clinical application under Good Manufacturing Practice (GMP).